<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047523</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1840-WD-302</org_study_id>
    <secondary_id>2021-001015-82</secondary_id>
    <nct_id>NCT05047523</nct_id>
  </id_info>
  <brief_title>Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease</brief_title>
  <official_title>A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson&#xD;
      disease (WD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who complete the 48 weeks of treatment in Period 1 will have the option to&#xD;
      receive ALXN1840 for 24 weeks in Period 2 (open-label extension).&#xD;
&#xD;
      Safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline To Week 48 In Non-ceruloplasmin-bound Copper (NCC) In Plasma</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Effect Versus Time Curve (AUEC) For NCC And Plasma Total Copper</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Change From Baseline To Week 48 Of Ceruloplasmin-bound Copper And Ceruloplasmin</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NCC Responder Rate</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Week 48 In The UWDRS Part II Total Score</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Week 48 In The UWDRS Part III Total Score</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time To Maximum Concentration (Tmax) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under The Plasma Concentration Versus Time Curve From Time 0 To The End Of The Dosing Interval (AUCtau) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-improvement (CGI-I), As Assessed By The Investigator</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Week 48 In Clinical Global Impression-severity (CGI-S), As Assessed By The Investigator</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Week 48 In Model For End-stage Liver Disease (MELD) Score (Ages 12 Years And Older) Or Pediatric End-stage Liver Disease (PELD) Score (Ages 3 To &lt; 12 Years)</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Week 48 In Modified Nazer Score</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>ALXN1840</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive their current therapy or initiate Standard of Care therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1840</intervention_name>
    <description>Administered as an oral tablet.</description>
    <arm_group_label>ALXN1840</arm_group_label>
    <other_name>Formerly WTX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Wilson Disease by Leipzig Score ≥ 4.&#xD;
&#xD;
          2. Adequate venous access to allow collection of required blood samples.&#xD;
&#xD;
          3. Able to swallow intact ALXN1840 tablets or mini-tablets.&#xD;
&#xD;
          4. Willing to avoid intake of foods and drinks with high contents of copper.&#xD;
&#xD;
          5. Willing and able to follow protocol-specified contraception requirements.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated hepatic cirrhosis or MELD score &gt; 13 (ages 12 to &lt;18) or PELD score &gt; 13&#xD;
             (ages 3 to &lt; 12).&#xD;
&#xD;
          2. Modified Nazer score &gt; 7.&#xD;
&#xD;
          3. Clinically significant gastrointestinal bleed within past 3 months.&#xD;
&#xD;
          4. Alanine aminotransferase (ALT) &gt; 2 × upper limit of normal (ULN) for participants&#xD;
             treated for &gt; 28 days with WD therapy or ALT &gt; 5 × ULN for treatment-naïve&#xD;
             participants or participants who have been treated for ≤ 28 days.&#xD;
&#xD;
          5. Marked neurological disease requiring either nasogastric feeding tube or intensive&#xD;
             inpatient medical care.&#xD;
&#xD;
          6. Hemoglobin less than lower limit of the reference range for age and sex.&#xD;
&#xD;
          7. History of seizure activity within 6 months prior to informed consent/assent.&#xD;
&#xD;
          8. Participants in renal failure, defined as in end-stage renal disease on dialysis&#xD;
             (chronic kidney disease stage 5) or estimated glomerular filtration rate &lt; 30&#xD;
             milliliters/minute/1.73 meter squared.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masood Sadaat, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>+1 855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Parkville</city>
        <zip>VIC 3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chiba</city>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Meguro-Ku</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Sapporo</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site3</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site 2</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wilson Disease</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

